Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: Impact of induction Ara-C dose and post-remission therapy

E. M. Sotomayor, S. Piantadosi, C. B. Miller, J. E. Karp, R. J. Jones, S. D. Rowley, S. H. Kaufmann, H. Braine, P. J. Burke, S. D. Gore

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

We report single institution outcome of brief, intensive ara-C-based chemotherapy using bone marrow transplantation as primary intensification for untreated adult patients with acute lymphoblastic leukemia (ALL). Overall disease-free and overall survival were inferior to those reported with prolonged chemotherapy modeled on pediatric protocols. Survival and disease-free survival were superior for patients receiving allogeneic BMT compared with chemopurged autologous transplant or maintenance chemotherapy (patients ineligible for or declining BMT). In multivariate analysis, non-L2-FAB, higher ara-C dose, absence of CNS disease, non-Ph1+ karyotype, allogeneic BMT, T cell phenotype, and younger age were associated with improved disease-free survival. Autologous BMT was not superior to chemotherapy, and appears unlikely to provide adequate curative treatment for most adult ALL patients if not followed by maintenance.

Original languageEnglish (US)
Pages (from-to)461-471
Number of pages11
JournalLeukemia Research
Volume26
Issue number5
DOIs
StatePublished - Apr 6 2002

Keywords

  • 4-Hydroperoxycyclophosphamide
  • Acute lymphoblastic leukemia (ALL)
  • Autologous
  • Bone marrow transplantation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: Impact of induction Ara-C dose and post-remission therapy'. Together they form a unique fingerprint.

  • Cite this